The transcription of ribosomal RNA by RNA Polymerase I (Pol I) is an essential step for cells to grow and thus is considered a therapeutic target for cancer treatment.

Hepatocellular carcinoma (HCC) is a complex disease where both the activation of the cyclic GMP-AMP synthase-stimulator of the interferon gene (cGAS-STING) pathway and the induction of immunogenic cell death (ICD) have proven effective immunotherapeutic strategies in some instances.

Ariceum Therapeutics GmbH has received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial (CITADEL-123) of 123I-ATT-001, its iodine-123 labeled PARP inhibitor, in patients with recurrent glioblastoma. The study is expected to begin in the U.K. in June of 2024.

Researchers from Capital Medical University have presented preclinical data for the novel PDZ-binding kinase (PBK) inhibitor, HI-TOPK-032, which is being developed for the treatment of cancer. The study aimed to assess the effects of the candidate on NK-92MI cell infiltration into ovarian tumors.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Arvinas Operations Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to a non-receptor tyrosine-protein kinase TYK2-targeting moiety via linker.

Iambic Therapeutics Inc. has disclosed quinazoline compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK2 and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of ovarian and breast cancer.

PARP inhibitors such as olaparib are used for the treatment of metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination deficiency (HRD), but a proportion of these patients do not respond to therapy or eventually develop resistance.